Picture of Filana Therapeutics logo

FLNA Filana Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Cassava Sciences Inc reports results for the quarter ended in June - Earnings Summary

* Cassava Sciences Inc  SAVA.OQ  reported quarterly adjusted
earnings of 13 cents​​ per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -63 cents.  The mean expectation of two analysts
for the quarter was for a loss of 40 cents per share. Wall
Street expected results to range from -44 cents to -36 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Cassava Sciences Inc's reported EPS for the quarter was 13
cents​.
    * The company reported quarterly net income of $6.16
million.
    * Cassava Sciences Inc shares had risen by 144.5% this
quarter and
gained 34.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 11.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

This summary was machine generated from LSEG data August 8 at
02:09 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.40          0.13           Beat
 Mar. 31 2024      -0.46          0.58           Beat
 Dec. 31 2023      -0.52          -0.50          Beat
 Sep. 30 2023      -0.77          -0.61          Beat

Recent news on Filana Therapeutics

See all news